All News
EULAR 2024 Rheumatology Roundup (6.21.2024)
Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna
Read Article
RA: update for women of child bearing potential (and men!)
Fertility in the context of RMDs is a daily concern for a lot of rheumatologists and patients.
https://t.co/RrkR2V3CI3 https://t.co/CRXUKxUqF2
Dr. John Cush RheumNow ( View Tweet)
Difficult-to-treat Rheumatoid Arthritis: Validation of the EULAR Definition
Dr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria.
https://t.co/oc3Aj60KsM https://t.co/40FMjbKEHF
Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 Daily Recap: Days 1 & 2
Dr. Jack Cush moderates EULAR 2024 RECAP for days 1 & 2 with Drs. Mrinalini Day and Yuz Yusof in Vienna, Austria.
https://t.co/gRMVUXhTxw https://t.co/YV8vjVUCJn
Dr. John Cush RheumNow ( View Tweet)
Rituximab to Treat Systemic Features of Sjogren's
Dr. Yuz Yusof discusses abstract OP0076 presented at Eular 2024 in Vienna, Austria.
https://t.co/9oJNz12cCI https://t.co/bZxpbf3PT9
Dr. John Cush RheumNow ( View Tweet)
Update on Sjogren's disease trials
With better endpoint and patient selection strategy over the last 4 years, many new therapies have met their endpoints/shown promising signal in the Phase 2 RCTs in Sjogren's disease.
https://t.co/qMxEX73BsM https://t.co/CQWaAIO4IK
Dr. John Cush RheumNow ( View Tweet)
New Treatments for Systemic Sclerosis
aHSCT for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed.
https://t.co/xUI0plrk42 https://t.co/DqGUhU6D1Z
Dr. John Cush RheumNow ( View Tweet)
Camels and psoriatic arthritis - a new treatment link
https://t.co/0SQt3UPmKu https://t.co/zvwH9iYtxX
Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 – Day 4 Report
The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations. Below is a synopsis of the half-day's action.
https://t.co/1lQcu1beOm https://t.co/QHMcFzaG48
Dr. John Cush RheumNow ( View Tweet)
We've Got to Talk about CAR T cells
Dr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria.
https://t.co/mrr5MWxeJz https://t.co/0FMLaAxaWV
Dr. John Cush RheumNow ( View Tweet)
Select your GCA Therapy
Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.
https://t.co/TPBeU7KaEq https://t.co/09uEzM3Kkd
Dr. John Cush RheumNow ( View Tweet)
Predicting Palindromic Prognosis
Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria.
https://t.co/Nc0XymI24l https://t.co/69qdLh63ct
Dr. John Cush RheumNow ( View Tweet)
Giant Cell Arteritis and Polymyalgia Rheumatica Update
Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria.
https://t.co/0V9Sle0GMU https://t.co/ixeT8L562C
Dr. John Cush RheumNow ( View Tweet)
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.
https://t.co/mv9DeZ9cez https://t.co/1OpT3MomO8
Dr. John Cush RheumNow ( View Tweet)
Update on low-dose glucocorticoids in SLE
GC have been the mainstay of treatment in SLE for nearly 75 yrs. GC induce anti-inflammatory effects, quickly relieve symptoms, and reduce mortality in life-threatening flares through various actions.
https://t.co/uEtWftvwEz https://t.co/nJlpELMj5W
Dr. John Cush RheumNow ( View Tweet)
Achieving drug-free remission in axSpA
In early axSpA, over 60% achieved sustained inactive disease. Male, non-smokers, low BASDAI scores had higher remission rates. Drug-free remission remains challenging.
https://t.co/Yv8a8C1hc9 https://t.co/JaYvfGry4P
Dr. John Cush RheumNow ( View Tweet)
POS0509 looks at time to diagnosis and #comorbidity burden in #axSpa
Retrospective study in French THIN database
Diagnostic delay remains common
Increased number of MSK & non-MSK manifestations & #comorbidities over time vs 1st presentation of back pain
#EULAR2024 @DrMiniDey https://t.co/egwDL1XjSw
Dr. John Cush RheumNow ( View Tweet)
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @Yuz6Yusof https://t.co/eSqOkBGBK2
Dr. John Cush RheumNow ( View Tweet)
Proportion of ILD patients on IS drugs has massively increased over time!
Also good to see practices are changing & MTX is slowly creeping in
Anna Maria Hoffmann-Vold, ILD management session #EULAR2024 @AurelieRheumo https://t.co/npa8O7g7l8
Dr. John Cush RheumNow ( View Tweet)
PMR has distinct patterns on MRI shoulder, possibly helping Dx.
#EULAR2024 OP0248 @drdavidliew
also
@bmj_rmdopen
https://t.co/0J3xUmb9yt where they say:
"Similar to our prior findings... the target of inflammation in PMR is the outer covering of a tendon, the peritendineum" https://t.co/AzWkg3z2vR
Dr. John Cush RheumNow ( View Tweet)